We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Sunesis Pharmaceuticals Inc | NASDAQ:SNSS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 5.32 | 4.72 | 4.75 | 0 | 01:00:00 |
SEC FILE
NUMBER
000-51531
|
|
CUSIP NUMBER
867328502
|
|
For Period Ended:
12/31/2008
|
||
¨
Transition Report on
Form 10-K
|
||
¨
Transition Report on
Form 20-F
|
||
¨
Transition Report on
Form 11-K
|
||
¨
Transition Report on
Form 10-Q
|
||
¨
Transition Report on
Form N-SAR
|
||
For the Transition Period Ended:
|
Read Instruction (on back page)
Before Preparing Form. Please Print or Type.
Nothing in this form shall be
construed to imply that the Commission has verified any information
contained herein.
|
SUNESIS PHARMACEUTICALS,
INC.
|
Full Name of
Registrant
|
Former Name if
Applicable
|
395
Oyster Point Boulevard, Suite 400
South
San Francisco, California 94080
|
Address of Principal Executive
Office, City, State and Zip Code
|
x
|
(a)
|
The reasons described in
reasonable detail in Part III of this form could not be eliminated without
unreasonable effort or expense;
|
||||
(b)
|
The subject annual report,
semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K,
Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before
the fifteenth calendar day following the prescribed due date; or the
subject quarterly report or transition report on Form 10-Q or subject
distribution report on Form 10-D, or portion thereof, will be filed on or
before the fifth calendar day following the prescribed due date;
and
|
|||||
(c)
|
The accountant’s statement or
other exhibit required by Rule 12b-25(c) has been attached if
applicable.
|
(1)
|
Name and telephone number of
person to contact in regard to this
notification
|
Eric
H. Bjerkholt
|
|
|
(650) 266-3500
|
(Name)
|
|
|
(Telephone
Number)
|
(2)
|
Have all other periodic reports
required under Section 13 or 15(d) of the Securities Exchange Act of 1934
or Section 30 of the Investment Company Act of 1940 during the preceding
12 months or for such shorter period that the registrant was required to
file such report(s) been filed? If answer is no, identify
report(s).
x
Yes
¨
No
|
(3)
|
Is it anticipated that any
significant change in results of operations from the corresponding period
for the last fiscal year will be reflected by the earnings statements to
be included in the subject report or portion
thereof?
x
Yes
¨
No
|
December
31
|
December
31
|
|||||||
2008
|
2007
|
|||||||
ASSETS
|
(Note
1)
|
|||||||
Current
assets:
|
||||||||
Cash and cash
equivalents
|
$ | 6,296,942 | $ | 11,726,126 | ||||
Marketable
securities
|
4,321,844 | 35,957,933 | ||||||
Prepaids and
other current assets
|
934,429 | 945,583 | ||||||
Total current
assets
|
11,553,215 | 48,629,642 | ||||||
Property and
equipment, net
|
612,241 | 4,238,498 | ||||||
Assets
held-for-sale
|
470,547 | - | ||||||
Deposits and
other assets
|
147,826 | 377,798 | ||||||
Total
assets
|
$ | 12,783,829 | $ | 53,245,938 | ||||
LIABILITIES
AND STOCKHOLDERS' EQUITY
|
||||||||
Current
liabilities:
|
||||||||
Accounts
payable and other accrued liabilities
|
$ | 4,207,923 | $ | 4,515,426 | ||||
Accrued
compensation
|
537,215 | 2,225,868 | ||||||
Current
portion of deferred rent
|
1,409,513 | - | ||||||
Current
portion of deferred revenue
|
27,083 | 1,227,031 | ||||||
Current
portion of equipment financing
|
- | 953,940 | ||||||
Total current
liabilities
|
6,181,734 | 8,922,265 | ||||||
Non current
portion of equipment financing
|
- | 1,352,684 | ||||||
Non-current
portion of deferred rent
|
110,919 | 1,576,734 | ||||||
Total
liabilities
|
6,292,653 | 11,851,683 | ||||||
Stockholders'
equity:
|
||||||||
Common
stock
|
3,441 | 3,437 | ||||||
Additional
paid-in capital
|
322,671,604 | 320,579,240 | ||||||
Deferred
stock-based compensation
|
- | (251,601 | ) | |||||
Accumulated
other comprehensive income
|
7,841 | 69,262 | ||||||
Accumulated
deficit
|
(316,191,710 | ) | (279,006,083 | ) | ||||
Total
stockholders' equity
|
6,491,176 | 41,394,255 | ||||||
Total
liabilities and stockholders' equity
|
$ | 12,783,829 | $ | 53,245,938 |
Note
1:
|
The
consolidated balance sheet at December 31, 2007 has been derived from the
audited financial
statements at
that date included in the Company's Form 10-K for the fiscal year ended
December 31,
2007.
|
Three months ended
December
31,
|
Twelve months ended
December
31,
|
|||||||||||||||
2008
|
2007
|
2008
|
2007
|
|||||||||||||
Revenue:
|
||||||||||||||||
Collaboration
revenue
|
$ | 12,500 | $ | 1,796,708 | $ | 4,917,340 | $ | 9,163,513 | ||||||||
License
revenue
|
- | 250,000 | 500,000 | 500,000 | ||||||||||||
Total
revenues
|
12,500 | 2,046,708 | 5,417,340 | 9,663,513 | ||||||||||||
Operating
expenses:
|
||||||||||||||||
Research and
development
|
4,617,239 | 8,268,413 | 26,285,294 | 36,060,470 | ||||||||||||
General and
administrative
|
2,195,211 | 2,820,543 | 11,524,198 | 13,569,578 | ||||||||||||
Restructuring
and impairment charges
|
393,158 | 345,426 | 5,782,903 | 1,563,274 | ||||||||||||
Total
operating expenses
|
7,205,608 | 11,434,382 | 43,592,395 | 51,193,322 | ||||||||||||
Loss from
operations
|
(7,193,108 | ) | (9,387,674 | ) | (38,175,055 | ) | (41,529,809 | ) | ||||||||
Interest
income
|
60,649 | 661,381 | 929,114 | 2,971,666 | ||||||||||||
Interest
expense
|
(17,224 | ) | (57,631 | ) | (171,308 | ) | (209,885 | ) | ||||||||
Other income,
net
|
222,551 | 5,949 | 231,622 | 7,108 | ||||||||||||
Net
loss
|
$ | (6,927,132 | ) | $ | (8,777,975 | ) | $ | (37,185,627 | ) | $ | (38,760,920 | ) | ||||
Basic and
diluted loss per share
|
$ | (0.20 | ) | $ | (0.26 | ) | $ | (1.08 | ) | $ | (1.20 | ) | ||||
Shares used in
computing basic and
diluted loss
per share
|
34,404,578 | 34,336,345 | 34,387,177 | 32,340,203 |
SUNESIS PHARMACEUTICALS,
INC.
|
(Name of Registrant as Specified
in Charter)
|
Date
|
|
April 1,
2009
|
|
By
|
|
/s/
Eric H.
Bjerkholt
|
|
|
|
Eric H.
Bjerkholt
Senior Vice
President, Corporate Development and Finance,
CFO
|
1 Year Sunesis Pharmaceuticals Chart |
1 Month Sunesis Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions